Supatonin

Quick links to important sections

Supatonin

Method of action: Anthelmintic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Supatonin

Property Description
Active ingredient Diethylcarbamazine (often as the citrate salt)
Form Tablets
Pharmacological class Anthelmintic / Anti-filarial agent
Common use Systemic antiparasitic treatment
Origin Synthetic compound

What is Supatonin and What Type of Drug is it?

Supatonin is a brand name for the specialized, synthetic medication whose active ingredient is Diethylcarbamazine. It is classified within the anthelmintic pharmacological group, specifically designated as a potent anti-filarial agent.

This classification defines its purpose: to fight and control parasitic worm infections, known as nematodes, in the human body. Diethylcarbamazine is a distinct, prescription-only compound developed through chemical synthesis, making it fundamentally different from natural or herbal remedies. Its status as an essential medicine underscores its critical role in managing these parasitic conditions. Diethylcarbamazine is effective for clearing microfilariae in filarial infections, allowing the drug to address the presence of the parasites in the body.


Composition and Physical Form of Diethylcarbamazine

The medicine is a single-ingredient product where the active substance is Diethylcarbamazine, commonly supplied as its stable salt form, Diethylcarbamazine citrate. The standard presentation of Supatonin is as tablets, which are formulated for oral route of administration.

This oral tablet form contains the specific active ingredient along with inactive pharmaceutical excipients necessary for stability and systemic absorption. The use of the citrate salt form is a standard pharmaceutical practice that ensures the molecule's effective absorption after ingestion.


High-Level Purpose and Function

The primary function of Diethylcarbamazine is to clear the parasitic load by rapidly acting on the circulating microfilariae (juvenile forms) and impacting the adult worms (macrofilaricidal effect). Its mechanism involves altering the surface of the parasites, which enhances their removal via the body's natural defense system, particularly the reticuloendothelial cells.

This focused mechanism achieves the general purpose of halting the parasite’s life cycle and reducing the density of the infection. By interrupting the proliferation and migration of the juvenile parasites, Supatonin aims to control the disease's progression and provide systemic relief from the infectious agent itself. The drug's primary therapeutic focus is on lymphatic filariasis and other related conditions, a typical use scenario that clinically demonstrates its specialized role in antiparasitic medicine.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Supatonin?

The profile of potential adverse reactions for Diethylcarbamazine (Supatonin) is officially documented, with the occurrence and severity of effects often related to the patient's existing parasitic burden. Mild to moderate adverse reactions are classified as common, while the incidence of serious adverse reactions is considered very low.

Reactions are often an allergic and inflammatory response to the dying parasites, typically starting within one to two hours after administration and persisting for several hours. Adverse reactions are classified according to the physiological systems affected:

  • Nervous System: Headache, dizziness, and drowsiness.
  • Gastrointestinal System: Nausea, vomiting, and abdominal pain.
  • Skin and Connective Tissue: Itching (Pruritus), rash, and hives (Urticaria).
  • General: Fever, chills, and muscle/joint pain (Myalgia/Arthralgia).
  • Lymphatic System: Swelling and inflammation of lymph nodes (Lymphadenitis/Lymphangitis).

Serious Adverse Reactions and Safety Constraints

Official labeling highlights specific serious risks, including potentially fatal encephalopathy and coma in individuals with a high Loa loa microfilarial load. Severe systemic and ocular reactions, such as the Mazzotti reaction and severe damage to the optic nerve, are documented safety concerns. Due to these risks, administration is officially not to be used in patients co-infected with onchocerciasis (River Blindness). Caution is noted for use in patients with a history of seizures or cardiac disorders, and a dosage reduction may be necessary for those with renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents describe specific clinical manifestations and required emergency actions related to an overdose of Supatonin (Diethylcarbamazine).

Immediate Medical Attention is Required

Immediate medical assistance must be sought if overexposure is suspected, or if severe outcomes occur. Regulators explicitly instruct individuals to seek immediate medical help or to contact Poison Control in situations of suspected overdosage.

Documented Overdose Manifestations Severe Systemic Outcome
Nausea, vomiting, headache Convulsions (noted in rare but serious cases)
Vertigo, drowsiness Tachycardia (rapid pulse)
Hypotension (low blood pressure) ---

Official Management and Supportive Measures

The management of Diethylcarbamazine overexposure is documented as symptomatic and supportive. There is no specific antidote listed in the official prescribing information.

Interventions described in the regulatory guidance include the provision of symptomatic treatment and the administration of activated charcoal. Supportive procedures may also involve providing adequate fluids to ensure optimal elimination. Continuous monitoring for adverse reactions and hospitalisation may be necessary based on the clinical assessment.

These statements define the risk profile and emergency response protocol strictly according to government drug authority guidance.

Therapeutic Uses of Supatonin

What Supatonin Treats: Main Uses and Benefits

Core Therapeutic Focus

Supatonin (Diethylcarbamazine) is commonly used in the management of specific parasitic infections and may assist with easing the associated discomfort. It is a key medication for addressing systemic parasitic conditions, including Lymphatic Filariasis, Loiasis, and Tropical Pulmonary Eosinophilia (TPE), which are infections caused by filarial worms. The medication is applied as a primary therapeutic approach for filariasis management.

A relevant therapeutic benefit is its use for managing the reduction of microfilariae (juvenile parasites) from the blood, which may assist with controlling the infection’s progression and may offer supportive management of the infection. This ability to assist with eliminating the parasitic load is generally applied in Mass Drug Administration (MDA) programs to support the reduction of transmission in endemic areas, and for prophylaxis (prevention) of Loiasis.

Symptom Management and Patient Comfort

The medication is commonly used to help manage symptoms related to heightened physiological activity and tissue inflammation triggered by the parasites. This supports the easing of symptoms associated with the periodic, localized swelling known as Calabar swellings and generalized itching (pruritus). Furthermore, it is relevant for addressing the distressing respiratory symptoms, such as persistent chronic cough and asthma-like episodes, that characterize TPE. By addressing these symptoms, Supatonin may assist patients during difficult episodes by easing distress and contributes to easing the overall symptom load.


Quick Fact: Relief for Inflammation-Driven Symptoms

Symptom Focus Therapeutic Benefit
Calabar Swellings Assists with managing acute, localized inflammation.
Chronic Cough Is relevant for managing TPE-related respiratory distress.
Microfilarial Load Is used for managing systemic parasitic activity.

Eligibility and Restrictions for Use

Who Can and Cannot Use Supatonin?

Supatonin (Diethylcarbamazine) is officially approved for use in adults and children over 2 years of age for specific parasitic conditions. Eligibility is strictly defined by regulatory documents, listing groups who are absolutely restricted (contraindicated) and those who require conditional or restricted use.

Contraindicated Populations

Use of Supatonin is strictly contraindicated in patients with known hypersensitivity to the medication. It is also prohibited for use during pregnancy and is generally not recommended for women who are breastfeeding. Critically, the drug is contraindicated in patients co-infected with Onchocerca volvulus (river blindness) due to the risk of severe adverse reactions.

Age and Comorbidity Restrictions

Treatment is typically excluded for infants and children under 2 years of age. Regulatory guidance specifies that the frail, elderly, and severely debilitated are normally excluded, particularly those with underlying cardiac or renal disease. The medicine requires caution and close monitoring for individuals with a history of convulsions and those with a high load of Loa loa microfilariae.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The regulatory interaction profile for Diethylcarbamazine (Supatonin) is defined by specific restrictions and pharmacokinetic findings documented in official government sources.

A primary restriction is the contraindication of co-administering the medicine in patients with a confirmed co-infection of the parasite Onchocerca volvulus (River Blindness). This severe restriction is explicitly stated in official prescribing information due to the potential for a severe systemic and ocular reaction.

Regarding interactions with other medicinal products, regulatory documents confirm that no other known interactions are generally documented. Specifically, co-administration with the anthelmintic Albendazole is formally noted as not significantly altering the pharmacokinetic (PK) profile of Diethylcarbamazine.

Interaction Type Interacting Substance/Condition Effect
Exposure Modification Alkaline Urine Systemic exposure (AUC) is increased and clearance is reduced.
Timing Requirement Meals/Food Must be administered after meals.

The drug's elimination is sensitive to urinary pH; the resulting increase in systemic exposure under alkaline conditions represents a documented physiological interaction. The only formal timing rule mandates administration after meals.

Mechanism of Action

Microfilariae Surface Modification and Immune System Engagement

The primary action of Diethylcarbamazine (Supatonin) is to simultaneously modify the circulating microfilariae and engage the host's immune system. It achieves this by acting as an inhibitor on key Arachidonic Acid enzymes (COX/5-LOX) in the parasite and physically altering the parasite's surface structure. This sensitization promotes recognition of the microfilariae, leading to their sequestration and destruction primarily by fixed phagocytic cells within the Reticuloendothelial System (RES), particularly in the liver.

Modulation of Host Inflammation

The mechanism includes an important modulatory effect on host physiology by acting as an inhibitor of the activation of the NF-kappaB transcription factor and host-side eicosanoid enzymes. This action modulates the molecular signaling cascades that lead to the generation of pro-inflammatory mediators. This modulation influences the host physiological responses that are triggered by the parasite and its byproducts.

Anti-Fecundity and Mechanistic Constraints

The action against the adult worms is characterized by a different mechanism that involves a transient disruption of muscle function via ion channel activation and long-term metabolic disruption. This results in impaired reproductive capacity (anti-fecundity), which limits the entry of microfilariae into the peripheral circulation. However, the clearance mechanism is highly dependent on a functional host immune response; the absence of these factors constrains the mechanism's systemic action.

Dosage and Administration Information

How to Use Supatonin

The medication Diethylcarbamazine (Supatonin) is intended for oral administration in the form of tablets. The standard process for use involves a structured approach focusing on dose escalation, frequency, and treatment course duration.


Administration Principles

Treatment typically begins with a low initial dose that is gradually increased over a period of 2 to 3 days to reach the full daily maintenance dose. This maximum daily dose, often calculated at 6 mg/kg/day or 9 mg/kg/day, is then continued for the duration of the course. For curative regimens, the total daily amount is administered in divided doses two or three times per day (TID).


Timing and Duration

Diethylcarbamazine is taken with or immediately after a meal. The course duration for individual treatment generally ranges from 12 to 21 days of continuous dosing. In community-level Mass Drug Administration programs, the usage pattern involves a single annual dose administered over a period of several years.


Special Administration Rules

Dosing for pediatric patients is determined on a weight-based (mg/kg) calculation, following the same initial titration schedule used for adults. A dosage reduction is applied when the medicine is used in patients with renal impairment. The tablets are intended to be swallowed whole.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Supatonin

The information presented here describes the types of clinical research conducted for Supatonin (Diethylcarbamazine) across its key uses, summarizing what the studies observed and where limitations exist. Findings describe group patterns, not personal outcomes, and this information does not constitute medical advice or treatment instruction.


Evidence for use in Lymphatic Filariasis

Research has been conducted to study the use of Supatonin for conditions associated with Lymphatic Filariasis. Studies utilized both Randomized Controlled Trials (RCTs) and large-scale community observational studies. The primary outcomes monitored investigated outcomes related to microfilariae clearance and adult worm markers.

Studies report how symptoms evolved in the observed populations, where patterns related to microfilariae change were recorded. Long-term outcomes are not well characterized regarding the sustained absence of the parasite markers following treatment cessation. Existing studies provide limited insight into whether the drug was studied for chronic clinical disease manifestations, such as lymphedema.


Evidence for use in Loiasis

Supatonin was studied for conditions involving periods of heightened symptoms associated with Loiasis. Research examined short-term symptom changes, utilizing randomized trials and clinical case series to explore patient responses. The main outcomes evaluated were related to measures of circulating microfilarial load and physical outcomes describing episodic changes, such as Calabar swellings. Evidence is limited regarding sustained infection clearance, and subgroup findings are uncertain for some individuals.


Evidence for use in Tropical Pulmonary Eosinophilia (TPE)

Supatonin was studied for conditions associated with TPE. Studies explored this condition using clinical case series and physiological research. The studies monitored outcomes related to systemic imbalance, specifically changes in blood eosinophil counts and Pulmonary Function Tests (PFTs). Evidence is limited regarding the complete and long-term recovery of lung function in all individuals. Follow-up durations were limited in some studies.

Frequently Asked Questions (FAQ)

Common questions about Supatonin (FAQ)

Q: Is it normal to feel tired or drowsy after starting Supatonin?

Official documentation regarding the medicine's adverse effects lists potential effects on the nervous system. These effects, which may include feeling drowsy, lassitude (a state of weariness), and weakness, are among those listed in the product information.

Q: Can teenagers or children be prescribed Supatonin?

According to official regulatory standards, the medicine is approved for use in adults and children who are over 2 years of age for its specified parasitic conditions. Dosing for children is determined based on factors including body weight, as described in official guidelines.

Q: Is Supatonin safe to use while breastfeeding or pregnant?

Regulatory documents indicate that the medicine is contraindicated (should not be used) during pregnancy. Furthermore, official product information indicates that it is generally not recommended for women who are breastfeeding.

Q: Is it okay to take Supatonin with coffee or caffeine products?

Official labeling does not list a specific interaction with caffeine or coffee. However, any questions regarding specific food, beverages, or supplements are typically directed to a healthcare provider for clarification.

Q: Does Supatonin affect blood pressure readings?

The official documentation lists a risk of orthostatic hypotension, which is a drop in blood pressure that can occur when standing up. Official documentation also notes caution regarding the use of this medicine in patients with pre-existing cardiac (heart) disorders.

Q: Does Supatonin require any special medical monitoring (e.g., blood tests)?

Regulatory guidance indicates that patients being treated for certain co-infections, such as river blindness (onchocerciasis), may require regular monitoring, specifically eye examinations. Other monitoring, such as blood counts or checks of liver function, is sometimes mentioned in relation to the medicine's use.

Q: Are there any known interactions with herbal products or natural remedies?

While labeling states no other known interactions are generally documented with medicinal products, it is generally advised that individuals provide their healthcare provider with a complete list of all supplements, herbal products, or natural remedies they are using.

Q: Does Supatonin interact with tobacco or nicotine products?

Official safety guidance often includes a general recommendation to avoid the consumption of tobacco products while using certain medications, though specific pharmacokinetic interaction with nicotine is not separately listed.

Q: How is Supatonin eliminated from the body?

Official pharmacokinetic data indicates that the elimination of the drug from the body is sensitive to the pH (acidity or alkalinity) of the urine. The drug’s clearance rate is known to slow down when the urine is alkaline, which can influence the amount of medicine present in the body’s system.

Q: Is Supatonin addictive or habit-forming?

Based on official pharmacological data, the medication is classified as not habit-forming. Official data does not indicate a risk of addiction or misuse associated with its use.

Q: Are there any major diet restrictions while taking Supatonin?

The primary administration instruction in official documents is that the medicine must be taken with or immediately after a meal. The official information does not list major, specific dietary restrictions, but the administration timing related to food is mandatory.

Q: What happens if I miss a scheduled dose of Supatonin?

The guidance in the product information suggests taking the dose as soon as it is remembered, unless the next dose is almost due. If so, the missed dose should typically be skipped, and the regular schedule resumed. Official instructions also specify that doses are not to be doubled.

Q: Is Supatonin a steroid or hormonal medication?

Supatonin is officially classified as an anthelmintic (a drug that fights parasitic worms) and is a synthetic chemical compound. It is not classified as a steroid or a hormonal medicine in any official regulatory documents.

Q: Is it true that Supatonin is only for short-term use?

The duration depends on the use case. Individual treatment courses are typically short (around 12 to 21 days). However, the medicine is also officially used in Mass Drug Administration programs, where it may be administered as a single annual dose over a period of several years as part of a public health strategy.

Q: Can Supatonin cause issues with sleep, such as insomnia?

The official product documentation lists drowsiness as a potential adverse effect. However, the regulatory documentation does not explicitly list insomnia (difficulty falling or staying asleep) as a known side effect.

Q: Can I drive a car or operate machinery while taking Supatonin?

Official safety guidance advises caution regarding driving or operating complex machinery. This precaution is noted because the medicine may cause side effects such as dizziness or drowsiness, particularly when an individual begins treatment.

Q: Why do some people need to take Supatonin for long periods?

Prolonged use, such as the single yearly dose given over several years in Mass Drug Administration (MDA) programs, is intended for widespread, systematic parasite elimination efforts within high-risk communities. This differs from the short duration of individual curative treatment.

Q: Does Supatonin affect my ability to concentrate or focus?

The regulatory documentation lists common nervous system effects, including dizziness and drowsiness. These effects, if experienced, may potentially impact an individual's ability to concentrate or focus.

Q: What if I take too much Supatonin by accident?

If an overdose is suspected, official guidance indicates that immediate medical attention should be sought or a poison control center should be contacted right away. This is a standard safety procedure for all medicines.

Q: Can Supatonin be taken with antacids or heartburn medication?

The drug’s elimination is sensitive to urinary pH. Official information advises consulting with a healthcare professional regarding the use of all over-the-counter medicines, including antacids, as they may potentially influence the drug's elimination.

Q: Is Supatonin available over the counter?

The medicine is classified as a prescription-only compound by regulatory authorities. This means it is not available over the counter and must be obtained with a prescription from a licensed healthcare professional.

Q: Can Supatonin cause changes in mood or emotional state?

The official adverse reaction documentation lists nervousness as a potential side effect of the medicine. This is the only related psychological or emotional effect explicitly noted in the regulatory documents.

Q: Why is Supatonin sometimes described as a 'selective' medication?

The drug is described in official documents as being highly specific for certain parasites. This selectivity relates to its targeted mechanism of action, which results in the rapid and effective clearance of microfilariae from the blood of infected individuals.

Q: Are there different forms or strengths of Supatonin available?

The standard presentation of the medicine is as tablets containing the active ingredient, Diethylcarbamazine citrate. While the form is consistent, regulatory labeling confirms that various strengths of the tablets may be available depending on the specific product and regional regulations.

Q: Can Supatonin be used for chronic pain management?

The official therapeutic indications for this medicine are restricted to treating filarial infections and tropical pulmonary eosinophilia. Chronic pain management is not an approved or indicated use according to regulatory guidelines.

How should Supatonin be stored and disposed of?

How to Store and Dispose of Supatonin?

Supatonin (Diethylcarbamazine Citrate tablets) requires strict storage conditions to maintain its effectiveness. It must be stored at a temperature not exceeding 30 C (86 F), and kept protected from both light and moisture. It is mandatory to store the medicine in the original, tightly closed container and ensure it never freezes. A critical stability rule is that the tablets must be discarded 30 days after the container is first opened.

All Supatonin must be kept out of the sight and reach of children. Unused or expired medication should be disposed of through an official drug take-back program. If one is unavailable, follow the procedure of mixing the product with an undesirable substance before discarding it in the household trash, in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Supatonin found in:

A-Z Index: